Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 3
2(40.0%)
5Total
Phase 2(3)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05640999Phase 2Recruiting

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Role: collaborator

NCT05611931Phase 3Recruiting

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Role: collaborator

NCT01244789Phase 2Active Not Recruiting

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Role: collaborator

NCT02009579Phase 2Completed

ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer

Role: collaborator

NCT02477644Phase 3Completed

Platine, Avastin and OLAparib in 1st Line

Role: collaborator

All 5 trials loaded